Manfred Accrombessi1, Jackie Cook2, Corine Ngufor3, Arthur Sovi3,4,5, Edouard Dangbenon4, Boulais Yovogan4, Hilaire Akpovi4, Aurore Hounto6, Charles Thickstun7, Gil G Padonou4, Filemon Tokponnon4, Louisa A Messenger3, Immo Kleinschmidt2,8,9, Mark Rowland3, Martin C Akogbeto4, Natacha Protopopoff3. 1. Faculty of Infectious and Tropical Diseases, Disease Control Department, London School of Hygiene and Tropical Medicine, WC1E 7HT, London, UK. manfred.accrombessi@lshtm.ac.uk. 2. Medical Research Council (MRC) International Statistics and Epidemiology Epidemiology Group, London School of Hygiene and Tropical Medicine, WC1E 7HT, London, UK. 3. Faculty of Infectious and Tropical Diseases, Disease Control Department, London School of Hygiene and Tropical Medicine, WC1E 7HT, London, UK. 4. Centre de Recherche Entomologique de Cotonou (CREC), Cotonou, Benin. 5. Faculty of Agronomy, University of Parakou, Parakou, Benin. 6. National Malaria Control Program, Ministry of Health, Cotonou, Benin. 7. School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Canada. 8. School of Pathology, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa. 9. Southern African Development Community Malaria Elimination Eight Secretariat, Windhoek, Namibia.
Abstract
BACKGROUND: Long-lasting insecticidal nets (LLINs) are currently the primary method of malaria control in sub-Saharan Africa and have contributed to a significant reduction in malaria burden over the past 15 years. However, this progress is threatened by the wide-scale selection of insecticide-resistant malaria vectors. It is, therefore, important to accelerate the generation of evidence for new classes of LLINs. METHODS: This protocol presents a three-arm superiority, single-blinded, cluster randomized controlled trial to evaluate the impact of 2 novel dual-active ingredient LLINs on epidemiological and entomological outcomes in Benin, a malaria-endemic area with highly pyrethroid-resistant vector populations. The study arms consist of (i) Royal Guard® LLIN, a net combining a pyrethroid (alpha-cypermethrin) plus an insect growth regulator (pyriproxyfen), which in the adult female is known to disrupt reproduction and egg fertility; (ii) Interceptor G2® LLIN, a net incorporating two adulticides (alpha-cypermethrin and chlorfenapyr) with different modes of action; and (iii) the control arm, Interceptor® LLIN, a pyrethroid (alpha-cypermethrin) only LLIN. In all arms, one net for every 2 people will be distributed to each household. Sixty clusters were identified and randomised 1:1:1 to each study arm. The primary outcome is malaria case incidence measured over 24 months through active case detection in a cohort of 25 children aged 6 months to 10 years, randomly selected from each cluster. Secondary outcomes include 1) malaria infection prevalence (all ages) and prevalence of moderate to severe anaemia in children under 5 years old, measured at 6 and 18 months post-intervention; 2) entomological indices measured every 3 months using human landing catches over 24 months. Insecticide resistance intensity will also be monitored over the study period. DISCUSSION: This study is the second cluster randomised controlled trial to evaluate the efficacy of these next-generation LLINs to control malaria transmitted by insecticide-resistant mosquitoes. The results of this study will form part of the WHO evidence-based review to support potential public health recommendations of these nets and shape malaria control strategies of sub-Saharan Africa for the next decade. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03931473 , registered on 30 April 2019.
RCT Entities:
BACKGROUND: Long-lasting insecticidal nets (LLINs) are currently the primary method of malaria control in sub-Saharan Africa and have contributed to a significant reduction in malaria burden over the past 15 years. However, this progress is threatened by the wide-scale selection of insecticide-resistant malaria vectors. It is, therefore, important to accelerate the generation of evidence for new classes of LLINs. METHODS: This protocol presents a three-arm superiority, single-blinded, cluster randomized controlled trial to evaluate the impact of 2 novel dual-active ingredient LLINs on epidemiological and entomological outcomes in Benin, a malaria-endemic area with highly pyrethroid-resistant vector populations. The study arms consist of (i) Royal Guard® LLIN, a net combining a pyrethroid (alpha-cypermethrin) plus an insect growth regulator (pyriproxyfen), which in the adult female is known to disrupt reproduction and egg fertility; (ii) Interceptor G2® LLIN, a net incorporating two adulticides (alpha-cypermethrin and chlorfenapyr) with different modes of action; and (iii) the control arm, Interceptor® LLIN, a pyrethroid (alpha-cypermethrin) only LLIN. In all arms, one net for every 2 people will be distributed to each household. Sixty clusters were identified and randomised 1:1:1 to each study arm. The primary outcome is malaria case incidence measured over 24 months through active case detection in a cohort of 25 children aged 6 months to 10 years, randomly selected from each cluster. Secondary outcomes include 1) malaria infection prevalence (all ages) and prevalence of moderate to severe anaemia in children under 5 years old, measured at 6 and 18 months post-intervention; 2) entomological indices measured every 3 months using human landing catches over 24 months. Insecticide resistance intensity will also be monitored over the study period. DISCUSSION: This study is the second cluster randomised controlled trial to evaluate the efficacy of these next-generation LLINs to control malaria transmitted by insecticide-resistant mosquitoes. The results of this study will form part of the WHO evidence-based review to support potential public health recommendations of these nets and shape malaria control strategies of sub-Saharan Africa for the next decade. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03931473 , registered on 30 April 2019.
Authors: Eric O Ochomo; Nabie M Bayoh; Edward D Walker; Bernard O Abongo; Maurice O Ombok; Collins Ouma; Andrew K Githeko; John Vulule; Guiyun Yan; John E Gimnig Journal: Malar J Date: 2013-10-24 Impact factor: 2.979
Authors: Richard M Oxborough; Raphael N'Guessan; Rebecca Jones; Jovin Kitau; Corine Ngufor; David Malone; Franklin W Mosha; Mark W Rowland Journal: Malar J Date: 2015-03-24 Impact factor: 2.979
Authors: Tinashe A Tizifa; Alinune N Kabaghe; Robert S McCann; Henk van den Berg; Michele Van Vugt; Kamija S Phiri Journal: Curr Trop Med Rep Date: 2018-02-08
Authors: Zawadi M Mboma; Hans J Overgaard; Sarah Moore; John Bradley; Jason Moore; Dennis J Massue; Karen Kramer; Jo Lines; Lena M Lorenz Journal: Malar J Date: 2018-03-01 Impact factor: 2.979
Authors: Rosemary S Lees; Jennifer S Armistead; Salum Azizi; Edi Constant; Christen Fornadel; John E Gimnig; Janet Hemingway; Daniel Impoinvil; Seth R Irish; William Kisinza; Natalie Lissenden; Henry D Mawejje; Louisa A Messenger; Sarah Moore; Corine Ngufor; Richard Oxborough; Natacha Protopopoff; Hilary Ranson; Graham Small; Joseph Wagman; David Weetman; Sarah Zohdy; Angus Spiers Journal: Insects Date: 2022-05-06 Impact factor: 3.139
Authors: Natacha Protopopoff; Mark Rowland; Jackline L Martin; Louisa A Messenger; Franklin W Mosha; Eliud Lukole; Jacklin F Mosha; Manisha Kulkarni; Thomas S Churcher; Ellie Sherrard-Smith; Alphaxard Manjurano Journal: Malar J Date: 2022-03-19 Impact factor: 2.979
Authors: Manfred Accrombessi; Martin C Akogbeto; Edouard Dangbenon; Hilaire Akpovi; Arthur Sovi; Boulais Yovogan; Constantin Adoha; Landry Assongba; Aurore Ogouyemi-Hounto; Germain Gil Padonou; Charles Thickstun; Mark Rowland; Corine Ngufor; Natacha Protopopoff; Jackie Cook Journal: Am J Trop Med Hyg Date: 2022-07-18 Impact factor: 3.707
Authors: Melissa A Iacovidou; Priscille Barreaux; Simon E F Spencer; Matthew B Thomas; Erin E Gorsich; Kat S Rock Journal: PLoS Comput Biol Date: 2022-09-19 Impact factor: 4.779
Authors: Nelson Grisales; Rosemary S Lees; James Maas; John C Morgan; Dimitri W Wangrawa; Wamdaogo M Guelbeogo; Sagnon N'Fale; Steven W Lindsay; Philip J McCall; Hilary Ranson Journal: Malar J Date: 2021-06-22 Impact factor: 2.979